Building on the success of the recent Emsculpt Neo and Emface launches, the non-invasive device manufacturer is expanding its team of experts.
A market leader in non-invasive body treatments and manufacturer of medical aesthetics equipment, BTL Aesthetics has expanded its team of global key opinion leaders (KOLs) with the appointment of Miss (Dr) Sherina Balaratnam MBBS MRCS(Edin) MSc (UCL).
With over 25 years of experience as a qualified doctor, Dr Balaratnam has spent the last 14 years practising within her current specialism of aesthetic medicine. She owns a multi-award-winning clinic, S-Thetics, in Buckinghamshire, UK.
With the news of Dr Balaratnam’s appointment, BTL’s ambition is to accelerate its continued growth on a global scale, building on the company’s 30 years of innovation, and following the success of the recent launches of Emsculpt Neo and Emface. Known for offering advanced non-invasive medical aesthetic solutions for body shaping, skin tightening and women’s intimate health, more BTL products are set to come to market soon.
As a KOL, Balaratnam, alongside BTL Aesthetics’ existing global team of experts, will see her insights, research and experience assist the research and development team with future technological development, as well as continuing to increase brand awareness and product education.
A number of BTL Aesthetics’ technologies are already in use at her Buckinghamshire clinic, meaning Dr Balaratnam is also able to share her deep understanding of these treatment protocols. This will be further supported by her proven success rate in delivering expert results in body and facial rejuvenation.
“I am honoured to have been invited to represent BTL in the capacity of global key opinion leader,” revealed Dr Balaratnam. “We are now in our 5th year of proudly hosting BTL technologies at my clinic, S-Thetics; starting with Emsculpt, then progressing to Emsculpt Neo, Emsella and now Emface and beyond. My interest and passion in aesthetics is in the field of regenerative science and medicine and, having worked so closely with BTL, I feel a strong alignment in our ethos for patient safety, innovation and enhancing our patients’ outcomes using multiple treatment modalities. Our patients continue to benefit from these best-in-class technologies and treatments, and I am looking forward to working with the BTL family on some exciting new projects.”
“We are very proud of our track record in research and development, and to have our KOLs as a part of the development of BTL devices and technologies – often at the embryonic stages,” commented BTL’s managing director Zbynek Pistak. “With their invaluable insights and support, we aim to break new frontiers in aesthetics and exceed the needs and expectations of the aesthetic market and patients alike. BTL’s mission is not only to have the best aesthetic results possible but also to put our focus on real, functional medicine which today has become a very important part of aesthetic medicine. Collaborating with the brightest minds in their fields will help us achieve our goals.”
For more information, visit btlaesthetics.com
